MHRA

MHRA

Richmond Pharmacology, the 1st Early Phase CRO to receive MHRA Standard and Supplementary Accreditation for 2 hospital based Clinical Trial Centers.Richmond Pharmacology. (RPL) have proudly received MHRA Standard and Supplementary Accreditation, a clear sign of our continued commitment to providing the highest level of subject safety on all studies conducted within our two hospital based Early Phase trial centres. RPL is unique in being the only Early Phase CRO in the UK to have two trial centres based in two acute NHS teaching hospitals.The supplementary accreditation confirms that RPL have attained the highest level of accreditation available in Europe. This permits RPL to perform the full range of Early Phase studies, including trials requiring a review of risk factors by the Expert Advisory Group (EAG).The combination of this accreditation award, our experience from conducting in excess of 400 Early Phase studies and our world-leading scientific advisory board means our sponsors can rely on RPL to continue to lead the industry in the conduct of FTIM studies, as well as other specialty areas such as TQT Studies, Japanese bridging studies, gastrointestinal studies and patient studies.For more information on the MHRA Phase I accreditation scheme visit the MHRA website.For further information on RPL's Early Phase facilities and expertise,please review our brochures.

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event